Article | October 12, 2023

Over The Hurdles: Taking Psychedelics From Schedule I To Pharmacy

By Richard Sidwell, Ph.D., Senior Vice President and Chief Scientific Officer, Societal CDMO


The emergence of DEA Schedule I psychedelics as a groundbreaking therapeutic for treating mental health conditions holds promise for a fresh approach to complex therapeutic areas. Recent studies suggest that psychedelics such as psilocybin, MDMA, and LSD could play a game-changing role in managing conditions such as depression, PTSD, and even addiction. With societal perceptions of these substances beginning to shift, we’re standing on the edge of a new era of research and discovery.

The recent wave of clinical studies utilizing psychedelics and the untapped therapeutic potential they hold has attracted a surge of funds flowing into the field. However, developing Schedule I psychedelics for legal pharmaceutical use comes with a unique set of challenges. Navigating strict regulatory guidelines and ensuring patient safety — which requires rigorous attention to handling, engineering controls, PPE, and security measures — can complicate the path to clinical trials. Learn how a partner with experience in handling scheduled substances and navigating FDA and DEA regulation can help you advance toward clinical research and drug development with ease.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online